Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
$3.19
+5.0%
$2.92
$0.40
$5.48
$54.19M0.27467,512 shs129,698 shs
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$1.20
+0.8%
$1.21
$0.64
$2.92
$48.21M-0.73509,226 shs5,025 shs
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.20
$0.17
$2.96
$13M-25.98N/AN/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
$1.58
+2.9%
$1.70
$1.40
$3.74
$51.99M0.01325,994 shs93,284 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
-1.62%0.00%+1.00%+164.35%+316.04%
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
+3.95%-7.12%-34.53%+81.19%-6.69%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%0.00%0.00%0.00%-60.96%
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
-3.16%-1.92%-8.38%-10.53%-48.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
0.3197 of 5 stars
0.03.00.00.01.70.80.0
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
2.8936 of 5 stars
3.53.00.00.02.40.81.3
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/AN/AN/AN/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
1.2854 of 5 stars
0.03.00.00.03.03.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
0.00
N/AN/AN/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
3.00
Buy$3.00151.05% Upside
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00
N/AN/AN/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
$391.24K138.51N/AN/A$0.56 per share5.70
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$14.97M3.22N/AN/A$2.54 per share0.47
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$110K0.00N/A47.17N/ANaN
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
N/AN/AN/AN/A$0.12 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
-$4.90M-$0.17N/AN/A-963.46%-46.76%-23.02%N/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$61.07M-$1.73N/AN/AN/AN/A-54.70%-44.75%11/5/2025 (Estimated)
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
-$410K-$0.020.00N/AN/AN/AN/AN/AN/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
-$23.25M-$1.38N/AN/AN/AN/A-497.29%-165.42%N/A

Latest CHHE, ABVC, BRNS, and MAIA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/A-$0.13N/A-$0.13N/AN/A
8/7/2025Q2 2025
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$0.29-$0.52-$0.23-$0.52N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/AN/AN/AN/AN/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/AN/AN/AN/AN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/A
0.42
0.42
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/A
7.89
7.89
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
N/A
2.19
2.19

Institutional Ownership

CompanyInstitutional Ownership
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
11.38%
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
25.20%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
5.65%

Insider Ownership

CompanyInsider Ownership
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
17.10%
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
10.70%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
31.30%
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
32.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
3016.98 million14.08 millionNot Optionable
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
10740.34 million36.02 millionN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
4064.95 million44.62 millionNot Optionable
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
932.99 million22.33 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC BioPharma stock logo

ABVC BioPharma NASDAQ:ABVC

$3.19 +0.15 (+4.97%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Barinthus Biotherapeutics stock logo

Barinthus Biotherapeutics NASDAQ:BRNS

$1.20 +0.01 (+0.84%)
As of 03:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

China Health Industries stock logo

China Health Industries OTCMKTS:CHHE

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.

MAIA Biotechnology stock logo

MAIA Biotechnology NYSEAMERICAN:MAIA

$1.58 +0.05 (+2.94%)
As of 03:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.